Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S6W-40315 · Session 6

What engagement it has with NHS Scotland regarding access to the drug, Vorasidenib, for the treatment of brain tumours, including ensuring …

Answered Asked by Beatrice Wishart LD Lodged 2 Sep 2025

The question

To ask the Scottish Government what engagement it has with NHS Scotland regarding access to the drug, Vorasidenib, for the treatment of brain tumours, including ensuring that there is sufficient funding available; in which NHS boards this treatment is presently offered, and how it will ensure that all patients in Scotland with brain tumours have an equal opportunity to access it.

The answer

Answered by Jenni Minto on 11 Sep 2025 · 9 days after it was lodged, on time

Vorasidenib (Voranigo®) does not currently have a marketing authorisation (sometimes referred to as a licence) from the Medicines and Healthcare products Regulatory Agency (MHRA) which means it cannot be marketed or sold in the UK. The marketing authorisation process involves the MHRA reviewing and assessing the evidence supporting a medicinal product’s quality, safety and efficacy.As a result, vorasidenib is being offered for a limited time by the pharmaceutical company, Servier, through a free-of-charge (FOC) pharmaceutical company-led early access programme. Health Boards have processes for considering the use of an unlicensed medicine, including through FOC early access programmes, on an individual case-by-case basis where the clinician feels it would benefit an individual. The Scottish Government does not hold data on these decisions.Individual Health Boards are responsible for decisions on the implementation and availability of medicines in their area. The Scottish Government has committed to investing rebates from the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) to fund the New Medicines Fund (NMF), which provides additional top-up funding to territorial Health Boards to support the cost of introducing new medicines. Since 2014/15, £906 million has been made available to Health Boards via the NMF.

In the Official Report

No contribution in the Official Report cites S6W-40315 by reference.